Hydroxytertatolol

Hydroxytertatolol
Clinical data
Other names	4-Hydroxytertatolol
ATC code	None;
Identifiers
	IUPAC name 8-{2-Hydroxy-3-[(2-methyl-2-propanyl)amino]propoxy}-4-thiochromanol;
PubChem CID	163871;
ChemSpider	143721;
CompTox Dashboard (EPA)	DTXSID70920605 ;
Chemical and physical data
Formula	C16H25NO3S
Molar mass	311.44 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES OC(CNC(C)(C)C)COc2cccc1c2SCCC1O;
	InChI InChI=1S/C16H25NO3S/c1-16(2,3)17-9-11(18)10-20-14-6-4-5-12-13(19)7-8-21-15(12)14/h4-6,11,13,17-19H,7-10H2,1-3H3; Key:RVGKVEPDZHPSBE-UHFFFAOYSA-N;

Hydroxytertatolol is a beta blocker.^[1]^[2] It is a derivative of tertatolol.

References

^ T. Lave; C. Efthymiopoulos; D. Christmann; J. C. Koffel; L. Jung (1995). "Determination of 4-Hydroxytertatolol Stereoisomers in Rat and Human Urine by High-Performance Liquid Chromatography". Journal of Liquid Chromatography. 18 (14): 2801–2812. doi:10.1080/10826079508009325.
^ Bastian G, Urien S, Brée F, Jolliet P, Rocher I, Crambes O, Tillement JP (1992). "Stereoselective binding of tertatolol and of 4-hydroxytertatolol to human plasma proteins". Eur J Drug Metab Pharmacokinet. 17 (3): 233–236. doi:10.1007/bf03190151. PMID 1362702.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.